Achillion Pharmaceuticals, Inc. announced the appointment of David Apelian, M.D., Ph.D., MBA, to the position of Executive Vice President and Chief Medical Officer, effective May 28, 2013. Dr. Apelian will assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV. In addition, Achillion also announced the expansion of its clinical operations group with the recent addition of Kevin Kucharski, formerly head of clinical operations at Pharmasset, who will serve as Senior Vice President of Clinical Operations. Dr. Apelian brings to Achillion more than 13 years of industry experience from Bristol-Myers Squibb, Schering Plough and GlobeImmune where he focused on hepatology and infectious disease clinical development. Dr. Apelian was Clinical Director in the Infectious Diseases Group at Bristol-Myers Squibb (BMS), serving as medical co-lead for the clinical development and NDA submission of entecavir for chronic hepatitis B viral infection (HBV). Mr. Kucharski comes to Achillion with more than two decades of clinical operations expertise, with a focus on conducting U.S. and global clinical trials, ranging from Phase 1 through Phase 4. Prior to joining Achillion, Mr. Kucharski was Vice President of Clinical Operations at Pharmasset since 2007, and then at Gilead Sciences following their acquisition of Pharmasset.

Achillion Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 03:30 PM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Michael D. Kishbauch, Chief Executive Officer, President and Director.

Achillion Pharmaceuticals, Inc. reported unaudited financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, the company reported a net loss of $11.7 million or $0.14 per basic and diluted share compared with a net loss of $9.1 million or $0.13 per basic and diluted share for the first quarter of 2012. No revenue was recognized for the three months ended March 31, 2013 compared with revenue of $2.5 million for the three months ended March 31, 2012. Revenue during the first quarter of 2012 was related to recognition of deferred revenue under the company's former collaboration with Gilead Sciences, Inc. Loss from operations was $11.8 million compared to $9.2 million reported a year ago.